----

----

**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549**

**FORM      10-K/A**

| x | **ANNUAL                  REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE                  ACT OF                  1934** |
|---|---------------------------------------------------------------------------------------------------------------------------------------------|

**For      the fiscal year ended December 31, 2005.**

**OR**

| o | **TRANSITION                REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE                ACT OF                1934** |
|---|-------------------------------------------------------------------------------------------------------------------------------------------|

**For      the transition period from ________ to ________.**

**Commission      File Number 000-30929**

**KERYX      BIOPHARMACEUTICALS, INC.**

**(Exact      name of registrant as specified in its charter)**

| **Delaware**(State                or other jurisdiction ofincorporation                or organization)                             | **13-4087132**(I.R.S.                EmployerIdentification                No.) |
|-------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
|                                                                                                                                |
| **750                Lexington Avenue****New                York, New York**(Address                of principal executive offices) |  **10022**(Zip                Code)                                        |

**Registrant’s      telephone number, including area code: (212) 531-5965**

**Securities      registered pursuant to Section 12(b) of the Act:**

**Securities      registered pursuant to Section 12(g) of the Act:**

**DOCUMENTS      INCORPORATED BY REFERENCE**

----

----

**Explanatory      Note**

----

**PART      IV**

**ITEM      15. EXHIBITS and FINANCIAL STATEMENT SCHEDULES**

| **(a)** | **3.** **Exhibits** |
|---------|--------------------------|

| **Exhibit** |                                                                                                                                                                        |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Number**  | **Exhibit                Description**                                                                                                                                      |
|        |                                                                                                                                                                        |
| 10.21*      | License                Agreement between Keryx Biopharmaceuticals, Inc. and Panion & BF                Biotech,  Inc.                dated as of November 7, 2005. |
|        |

----

| * | Confidential                  treatment has been requested with respect to the omitted portions                  of this                  exhibit. |
|---|----------------------------------------------------------------------------------------------------------------------------------------------------|

----

**SIGNATURES          **

|                                  |                                                                                                                   |                                                    |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
|                                  | **KERYX              BIOPHARMACEUTICALS, INC.**                                                                        |
|                             |                                                                                                              |                                               |
| Date: May              10, 2006. | By:                                                                                                          | /s/ Ronald              C.              Renaud, Jr |
|                                  | Ronald              C. Renaud, JrSenior                Vice President, Chief Financial Officer, Secretary andTreasurer |

----

**EXHIBIT      INDEX**

| **Exhibit** |   |                                                                                                                                                                        |
|-------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Number**  |   | **Exhibit                Description**                                                                                                                                      |
|             |   |                                                                                                                                                                        |
| 10.21*      |   | License                Agreement between Keryx Biopharmaceuticals, Inc. and Panion & BF                Biotech,  Inc.                dated as of November 7, 2005. |
|        |   |                                                                                                                                                                        |

----

| * | Confidential                    treatment has been requested with respect to the omitted portions                    of this                    exhibit. |
|---|----------------------------------------------------------------------------------------------------------------------------------------------------------|

----